{"id":180863,"date":"2026-02-15T23:34:10","date_gmt":"2026-02-16T04:34:10","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180863"},"modified":"2026-02-15T23:34:10","modified_gmt":"2026-02-16T04:34:10","slug":"earnings-summary-akums-drugs-pharmaceuticals-reports-14-8-revenue-growth-in-q3-fy26-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-summary-akums-drugs-pharmaceuticals-reports-14-8-revenue-growth-in-q3-fy26-results\/","title":{"rendered":"Earnings Summary &#8211; Akums Drugs &amp; Pharmaceuticals Reports 14.8% Revenue Growth in Q3 FY26 Results"},"content":{"rendered":"\n<p><strong>Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS),<\/strong> a pharmaceutical contract development and manufacturing organization (CDMO) announced its third-quarter and nine-month financial results for fiscal year 2026 on February 13, 2026. On the day results were released, the stock closed at \u20b9484.95, representing a one-day gain of \u20b933.60 or 7.44%.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Quarterly Results<\/strong><\/h2>\n\n\n\n<p>Consolidated revenue for the quarter was \u20b91,160 crore, representing a 14.8% increase over the \u20b91,010 crore reported in the same period last year. Adjusted Profit After Tax (PAT) grew 29.5% year-on-year to \u20b986 crore, while Adjusted EBITDA reached \u20b9147 crore with a margin of 12.7%. Segment revenue shares included CDMO at 79.0%, domestic branded formulations at 9.9%, and API at 4.7%. The company reported \u20b918 crore in exceptional expenses and \u20b934 crore in other income for the period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Annual Performance Context<\/strong><\/h2>\n\n\n\n<p>For the first nine months of FY26, consolidated total income reached \u20b93,295 crore, a 6.4% increase over the \u20b93,097 crore reported in the prior year. Nine-month revenue stood at \u20b93,201 crore with an adjusted EBITDA of \u20b9370 crore, representing a 1.0% growth. Adjusted PAT for the nine-month period was \u20b9193 crore, a 1.6% increase compared to \u20b9190 crore in the previous year. Margins for the nine-month period were 11.6% for adjusted EBITDA and 5.9% for adjusted PAT.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Business and Operations Update<\/strong><\/h2>\n\n\n\n<p>The CDMO segment achieved double-digit volume growth despite a 1.2% growth rate in the broader Indian Pharmaceutical Market, while international branded formulation exports more than doubled on a sequential basis. API pricing remained under pressure, though the company noted &#8220;initial signs of stabilization&#8221; in select molecules and reported overall capacity utilization of 47%. Revenue growth was driven by the CDMO and international formulation segments, while the company continued to consolidate its trade generics business. The company received EU GMP certification for its oral solids and oral liquids facilities and its first UK MHRA approval for Rivaroxaban tablets. Sandeep Jain stated, \u201cThe EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams\u201d.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Forward Outlook<\/strong><\/h2>\n\n\n\n<p>The company plans to begin supplies from its European CDMO project in FY 28. Commercial supplies for the Zambia project from Indian facilities are expected to begin in the first half of FY27. Sanjeev Jain stated the company remains &#8220;focused on our long-term growth drivers that include innovation, operational efficiency, cost controls and strategic partnerships&#8221;. Company issued no further specific financial guidance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Performance Summary<\/strong><\/h2>\n\n\n\n<p>The company reported \u20b91,160 crore in quarterly revenue, led by volume growth in the CDMO vertical. Profitability improved year-on-year with adjusted PAT reaching \u20b986 crore despite ongoing pricing pressure in the API segment. The company advanced its global regulatory standing with certifications from the European Union and the United Kingdom. Overall capacity utilization reached 47% as newer facilities continued to ramp up.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS), a pharmaceutical contract development and manufacturing organization (CDMO) announced its third-quarter and nine-month financial results for fiscal year 2026 on February 13, 2026. On the day results were released, the stock closed at \u20b9484.95, representing a one-day gain of \u20b933.60 or 7.44%. Quarterly Results Consolidated revenue for the [&hellip;]<\/p>\n","protected":false},"author":2396,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[16532,8157,10162],"class_list":["post-180863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-healthcare-stocks","tag-akums","tag-healthcare","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":180863,"position":0},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168657,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-12-rise-in-revenue\/","url_meta":{"origin":180863,"position":1},"title":"Akums Drugs &#038; Pharmaceuticals Ltd Q4FY25; 12% rise in Revenue","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. Financial Results: Akums Drugs & Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b91,056.00 Crores up from \u20b9944.00 Crore year on year, a rise of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172881,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-q2-fy26-earnings-results\/","url_meta":{"origin":180863,"position":2},"title":"Akums Drugs Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 3, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004 as India's leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26. Financial Highlights: Revenues declined 1.45% year-on-year to \u20b91,018 crore from \u20b91,033 crore, with CDMO up 0.7% to \u20b9804 crore but API\/international formulations down.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177762,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-performance-market-environment-and-competitive-position\/","url_meta":{"origin":180863,"position":3},"title":"Innova Captab Limited Performance, Market Environment, and Competitive Position","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP) has emerged as a noteworthy player in India's pharmaceutical landscape, combining contract development and manufacturing (CDMO) services with a branded generics business. In recent quarters, the company has delivered strong top-line growth coupled with improving profitability, reflecting both operational execution and expanding market reach. In\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173791,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-pharmaceuticals-limited-akums-q2-2025-earnings-call-transcript\/","url_meta":{"origin":180863,"position":4},"title":"Akums Drugs &#038; Pharmaceuticals Limited (AKUMS) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Limited (NSE: AKUMS) Q2 2025 Earnings Call dated Nov. 11, 2024 Corporate Participants: Sahil Maheshwari \u2014 General Manager, Strategy Sandeep Jain \u2014 Managing Director Sumeet Sood \u2014 Chief Financial Officer Amrut Medhekar \u2014 Chief Executive Officer Analysts: Prashant Nair \u2014 Analyst Abdulkader Puranwala \u2014 Analyst Ashish\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":181326,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-pharmaceuticals-limited-akums-q3-2026-earnings-call-transcript\/","url_meta":{"origin":180863,"position":5},"title":"Akums Drugs &#038; Pharmaceuticals Limited (AKUMS) Q3 2026 Earnings Call Transcript","author":"News desk","date":"February 19, 2026","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Limited (NSE: AKUMS) Q3 2026 Earnings Call dated Feb. 16, 2026 Corporate Participants: Sandeep Jain \u2014 Co-Founder and Managing Director Sumeet Sood \u2014 Chief Financial Officer Sahil Maheshwari \u2014 Head Strategy Ankit Jain \u2014 Investor Relations Analysts: Unidentified Participant Abdulkader Puranwala \u2014 Analyst Vivek Agrawal \u2014\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2396"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180863"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180863\/revisions"}],"predecessor-version":[{"id":180865,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180863\/revisions\/180865"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}